
    
      A prospective, open-label, randomized control trial in a tertiary university-affiliated
      medical center between April to August 2020. Overall, 100 women will be randomly allocated to
      undergo ultrasound exam either with the use of VR (study group) or with standard treatment
      (control group). The primary outcome measures includ self-reported pain, anxiety scores, and
      vital parameters as pulse rate (PR) and respiratory rate (RR). Pain and anxiety outcomes were
      measured as numeric rating scores.
    
  